Become a Member | Print Page | Contact Us | Report Abuse | Sign In
News
Share |
  

October 15, 2019

Board of Directors Announces a  New International Board Member 

  


ITOG strives to foster a climate of purposeful inclusion of all people. We value the diversity of racial, cultural identity, geographical, institutional, and medical specialty. To this end, ITOG the Board of Directors voted unan-imously to amend th


  ITOG  is pleased to announce that Dr. Sophie Leboulleux has been elected as the newest international member of the ITOG Board of Directors. Sophie Leboulleux is board certified in endocrinology, nuclear medicine and oncology.She works in the Department of Nuclear Medicine and Endocrine On-cology in Villejuif, France where she is responsible for the Thyroid Cancer Multidisciplinary Team. Her current clinical interests include treatment and follow up of thyroid cancer from thyroid nodule to radioactive iodine refractory thyroid cancer and imaging of cancer with TEP. Her current research is focused on the role of adjuvant radioactive treatment administration and on radioactive refractory thyroid cancer. She leads a prospective randomized study on the utility of postoperative radioactive iodine treatment, a prospective study on redifferentiation and has been co-investigator for trials in radioactive iodine refractory differentiated thyroid cancer and medullary thyroid cancer. She is Associate Profes-sor, Chief of the Department of Nuclear Medicine in Villejuif and Associate Professor in the Department of Endocrine Oncology. ITOG is fortunate to have such qualified individuals to serve on the board of directors, ensuring commitment to the mission of ITOG in catalyzing effective treatments for thyroid cancer. Board of Directors voted unan-imously to amend the bylaws to require a minimum of one international member on the ITOG Board of Directors. This required a nomination and election of one seat for an International Member. The term on the board will be three years, and will be defined as any ITOG member at an institution outside of the United States.e bylaws to require a minimum of one international member on the ITOG Board of Directors. This required a nomination and election of one seat for an International Member. The term on the board will be three years, and will be defined as any ITOG member at an institution outside

 of the United States. 

October 15, 2019
ITOG Leadership UpdatesITOG Leadership Updates
 ITOG is grateful to Dr. Eric Sherman and Dr. John Andrew “Drew” Ridge, newly elected as the Chair and Co-Chair of the Protocol Committee, respectively. Dr. Eric Sherman, formerly Co-Chair of the Proto-col Committee, is a medical oncologist at Memorial Sloan-Kettering (MSK) and has presented at numer-ous ITOG Annual Meetings. He will serve alongside Dr. Drew Ridge, Professor of Surgical Oncology and of Molecular and Translational Medicine at Fox Chase Cancer Center.

October 15, 2019

 ITOG is pleased to announce a new co-chair for the  Website Communications

 Dr. Carmelo New Protocol Committee Co-Chair Dr. Drew Ridge with ITOG Chair Dr. Manisha
Shah and Co-Chair Dr. Eric Sherman and outgoing Co-Chair Dr. David Pfister. Nucera, Assistant Professor 
at Harvard Medical School. Dr. Jennifer Sipos, Associate Professor of Medicine at The Ohio State University School of Medicine, remains the chair; a position she has held since 2017.  
The ITOG community is fortunate to include these effective members in the leadership team and looks forward to benefiting from their ongoing efforts.
Connect With Us

International Thyroid Oncology Group

5166 Commercial Drive

Yorkville, New York 13495

Our mission
To catalyze a cure for the most challenging thyroid cancers through the collaborative efforts of our unique multidisciplinary team of leading physicians, scientists, and advocates to design, coordinate, and prioritize state-of-the-art clinical trials and correlative science.